Prostate Cancer - Results from #280

Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [177Lu]Lu-PSMA-617 in the Phase 3 VISION Trial. September 11, 2024

Hospital-Level Variability in the Adoption of Image-Guided Focal Therapy for Localized Prostate and Kidney Cancer. September 11, 2024

Prevention of Prostate Cancer Metastasis by a CRISPR-delivering Nanoplatform for Interleukin-30 Genome Editing. September 11, 2024

The Impact of Radical Prostatectomy Versus Radiation Therapy on Cancer-Specific Mortality for Nonmetastatic Prostate Cancer: Analysis of an Other-Cause Mortality Matched Cohort. September 11, 2024

Artificial Intelligence Improves the Ability of Physicians to Identify Prostate Cancer Extent. September 11, 2024

A new silicon phthalocyanine dye induces pyroptosis in prostate cancer cells during photoimmunotherapy. September 10, 2024

Emergency and non-emergency routes to cancer diagnoses in 2020 and 2021: A Population-based study of 154,863 patients. September 10, 2024

Effect of concomitant medications on treatment response and survival in non-metastatic castrate resistant prostate cancer: Exploratory analysis of the SPARTAN trial. September 10, 2024

Apalutamide for non-metastatic castration-resistant prostate cancer (nmCRPC): real world data of a multicenter study. September 10, 2024

Predictive factors of hemoglobin drop after robot-assisted radical prostatectomy: a single center prospective study. September 10, 2024

Treatment Patterns and Survival Outcomes Among Androgen Receptor Pathway Inhibitor-Experienced Patients With Metastatic Castration-Resistant Prostate Cancer. September 9, 2024

Active surveillance selection and 3-year durability in intermediate-risk prostate cancer following genomic testing. September 9, 2024

Cardiovascular events among men with prostate cancer treated with androgen receptor signaling inhibitors: a systematic review, meta-analysis, and network meta-analysis. September 9, 2024

Effect of PSMA PET/CT on the Use of Bone Scintigraphy for Prostate Cancer at a University Hospital System. September 9, 2024

Impact of TP53 loss-of-function alterations on the response to PSMA radioligand therapy in metastatic castration-resistant prostate cancer patients. September 9, 2024

Development of prediction models based on risk scores for clinically significant prostate cancer on MRI/TRUS fusion biopsy. September 6, 2024

PARP Inhibitor Addition to Androgen Receptor Pathway Inhibitors in Metastatic Castration-resistant Prostate Cancer Should Be Limited to BRCA Mutation Carriers. September 6, 2024

The Use of Lurbinectedin for the Treatment of Small Cell and Neuroendocrine Carcinoma of the Prostate. September 6, 2024

VISION: An Individual Patient Data Meta-analysis of Randomised Trials Comparing Magnetic Resonance Imaging Targeted Biopsy with Standard Transrectal Ultrasound Guided Biopsy in the Detection of Prostate Cancer. September 6, 2024

Estimated incidence of disruptions to event-free survival from non-metastatic cancers in New South Wales, Australia - a population-wide epidemiological study of linked cancer registry and treatment data. September 6, 2024

Page 15 of 1435